Affiliation:
1. Dalian Boyuan Medical Lab Co. Ltd Dalian PR China
2. Key Laboratory of Liaoning Tumor Clinical Metabolomics (KLLTCM) Jinzhou Medical University Jinzhou PR China
Abstract
AbstractLiver cirrhosis is currently the twelfth leading cause of death globally and the sixth leading cause of death in China. Its treatment is expensive. Changes in the composition of the serum bile acid pool are sensitive indicators of the severity of liver cirrhosis. In this study, a novel LC–tandem mass spectrometry (LC–MS/MS) method was developed and used to simultaneously determine 15 bile acids in human serum in patients with decompensated cirrhosis. Sample preparation involved spiking with isotope internal standards followed by protein precipitation. The analytical run time was 5 min. The LC–MS/MS method was fully validated according to Clinical and Laboratory Standards Institute (CLSI) C62A and the consensus of method development and validation of liquid chromatography–tandem mass spectrometry in clinical laboratories. The method achieved an acceptable coefficient of variation for precision (0.83%–14.80%) and accuracy (89.39%–107.62%). Finally, as proof of applicability, the method was applied to patients with decompensated cirrhosis in routine clinical sample analysis. The degree of variation of different bile acids was clearly shown. These results indicated that abnormal metabolic pathways might play important roles in decompensated cirrhosis.
Subject
Clinical Biochemistry,Drug Discovery,Pharmacology,Molecular Biology,General Medicine,Biochemistry,Analytical Chemistry